Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20394068 | 1.00 | CA2 (0.32) | CA2ALDH1A1IDO1 | |
| SCHEMBL1097047 | 0.89 | ALDH1A1 (0.32) | CA2ALDH1A1IDO1 | |
| SCHEMBL23818791 | 0.87 | TSHR (0.36) | ALDH1A1IDO1 | |
| SCHEMBL25401467 | 0.84 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL25277740 | 0.84 | ALDH1A1 (0.34) | CA2ALDH1A1IDO1 | |
| SCHEMBL24371818 | 0.83 | TSHR (0.33) | ALDH1A1 | |
| SCHEMBL31228273 | 0.83 | TSHR (0.33) | ALDH1A1 | |
| SCHEMBL17958882 | 0.83 | TSHR (0.33) | ALDH1A1 | |
| SCHEMBL20405995 | 0.83 | TSHR (0.33) | ALDH1A1 | |
| SCHEMBL19221819 | 0.83 | TSHR (0.33) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1152009-B2 | NOVEL NUCLEOSIDES AND OLIGONUCLEOTIDE ANALOGUES | DAIICHI SANKYO CO LTD (JP) | 2017-09-06 | — | — | EP | disclosed |
| US-8957201-B2 | Oligonucleotide analogues and methods utilizing the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-02-17 | — | — | US | disclosed |
| US-20110009471-A1 | Oligonucleotide analogues and methods utilizing the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-01-13 | — | — | US | disclosed |
| US-7335765-B2 | Nucleoside and oligonucleotide analogues | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-02-26 | — | — | US | disclosed |
| EP-1152009-B1 | NOVEL NUCLEOSIDES AND OLIGONUCLEOTIDE ANALOGUES | SANKYO CO (JP) | 2005-01-26 | — | — | EP | disclosed |
| EP-1152009-A1 | NOVEL NUCLEOSIDES AND OLIGONUCLEOTIDE ANALOGUES | Sankyo Company, Limited (JP) | 2001-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009471-A1 | Oligonucleotide analogues and methods utilizing the same | NSUN2, RNGTT, DUT | CA2 1574/4885ALDH1A1 1693/4885IDO1 2863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.